Please use this identifier to cite or link to this item:
|Title:||Discovery of 17 Gliptins in 17-Years of Research for the Treatment of Type 2 Diabetes: A Synthetic Overview|
|Authors:||Kushwaha, R N|
Katti, S B
|Keywords:||Discovery;Gliptins;17-Years of Research for the Treatment;Type 2 Diabetes;Ynthetic Overview|
|Description:||Gliptins, commonly known as clinical DPP-IV inhibitors have become a new class of potential drug candidate and are being hoped as a permanent eraser for type 2 diabetes. Therefore, gliptins have been a centre of research and development. As a result of the efforts made towards developing effective gliptins, the first clinical proof of concept for efficacy was confirmed in 1998 when NVP-DPP728 came into focus. Thus, from 1998 to 2014, these 17-years of the heightened research towards drug discovery has resulted in seventeen gliptins. Among these, eight gliptins are currently approved and in clinical usages for type 2 diabetes therapies, while others are in different stages of clinical trials. This review covers the various approaches and methodologies used in the syntheses of only those DPP-IV inhibitors in clinical uses having suffix gliptin. In addition, it also encompasses their biological activity and their binding interactions in the active site of DPP-IV that are responsible for their drug candidacy.|
|Other Identifiers:||Chemistry & Biology Interface, 2014, 4(3), 137-162|
|Appears in Collections:||Medicinal and Process Chemistry|
Files in This Item:
Click on the URI links for accessing contents.
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.